RAC Insider Trading

Insider Ownership Percentage: 27.00%
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Race Oncology Insider Trading History Chart

This chart shows the insider buying and selling history at Race Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Race Oncology Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for RAC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Race Oncology Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/30/2024Mary HarneyInsiderIssued1,170A$0.75A$877.50
12/4/2023Phillip(Phil) LynchInsiderIssued21,457A$0.89A$18,989.45
12/1/2023Peter (Pete) SmithInsiderIssued440,019A$0.85A$374,016.15
3/3/2023Daniel SharpInsiderIssued110,392A$2.27A$250,589.84
2/7/2023Daniel TillettInsiderBuy6,793A$1.92A$13,042.56
1/13/2023Daniel TillettInsiderBuy25,550A$196.57A$5,022,312.40
12/20/2022Daniel TillettInsiderBuy46,737A$2.12A$99,175.91
11/14/2022Daniel TillettInsiderBuy2,307,925A$0.21A$475,432.55
11/3/2022Daniel TillettInsiderBuy4,826A$2.31A$11,152.89
10/5/2022Daniel TillettInsiderBuy23,914A$1.87A$44,814.84
9/23/2022Daniel TillettInsiderBuy83,954A$1.97A$165,473.33
5/16/2022Mary HarneyInsiderExpiry400A$1.89A$754.00
3/4/2022Daniel TillettInsiderBuy20,301A$2.75A$55,766.85
1/10/2022John CullityInsiderSell300,000A$3.32A$995,100.00
12/21/2021Phillip(Phil) LynchInsiderIssued10,000A$3.00A$30,000.00
12/10/2021Daniel TillettInsiderBuy17,729A$3.34A$59,179.40
11/12/2021John CullityInsiderExercise3,000,000A$0.24A$711,000.00
11/4/2021John CullityInsiderSell217,878A$3.26A$710,064.40
9/2/2021John CullityInsiderSell61,745A$3.12A$192,767.89
8/23/2021John CullityInsiderBuy1,893,939A$0.10A$187,499.96
See Full Table

SEC Filings (Institutional Ownership Changes) for Race Oncology (ASX:RAC)

Race Oncology logo
Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
Read More on Race Oncology

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

76,322 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.53

Who are the company insiders with the largest holdings of Race Oncology?

Race Oncology's top insider investors include:
  1. Daniel Sharp (Insider)
  2. Daniel Tillett (Insider)
  3. Mary Harney (Insider)
  4. Peter (Pete) Smith (Insider)
  5. Phillip(Phil) Lynch (Insider)
Learn More about top insider investors at Race Oncology.